Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Q3 FY25 revenue up 24% to Rs 3,230 crore
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
